The AHA urge Congressional leaders to support the bipartisan Healthcare Workforce Resilience Act (H.R. 6788/S.3599), and include it in forthcoming COVID-19 relief legislation
Letters
Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.
Latest
AHA comments on the Department of Health and Human Services’ proposed rule to set expiration dates for its regulations (subject to certain exceptions), unless the department periodically assesses the regulations to determine if they are subject to review, and if they are, performs a review. Subject to this review, HHS would be able to unilaterally retain, modify or eliminate the regulation.
The AHA asks the Department of Health and Human Services (HHS) to take additional steps to increase flexibilities for providers responding to the COVID-19 pandemic.
Nineteen organizations representing physicians and hospitals, including the AHA, urge congressional leaders to support legislation to freeze the thresholds for clinicians to qualify for advanced alternative payment model incentive payments for the 2021 and 2022 performance years.
Confronting the challenges of the pandemic is imperative to saving American lives. Real-time data and information on the supply of therapeutics, testing supplies, personal protective equipment, ventilators, hospital bed capacity and workforce availability to plan for further deployment of the nation’s assets needs to be shared to save countless lives.
The Department of Health and Human Services should fully reinstate its June COVID-19 Provider Relief Fund reporting requirements, AHA said again today in a letter to the agency.
The AHA on Friday sent a letter to the Health Resources and Services Administration’s Office of Pharmacy Affairs urging the agency to order drug manufacturers and their vendor Kalderos to immediately halt their conversion of the 340B program to a back-end rebate program.
AHA comments on the Centers for Medicare & Medicaid Services’ proposed revision to the definition of “reasonable and necessary” for purposes of Medicare coverage determinations.
AHA letter urging the Centers for Medicare & Medicaid Services to immediately withdraw the new condition of participation that threatens to expel hospitals from the Medicare program if they fail to comply with “frequently changing and confusing” COVID-19 data collection efforts.
In a letter to Senator Lamar Alexander and Representative Greg Walden, AHA expresses strong support for the 340B Drug Pricing Program.